Epi-743
Autism Spectrum Disorder
Edison Pharmaceuticals IncPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Autism Spectrum Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Holland Bloorview Kids Rehabilitation Hospital | Phase 4 | BBB |
Risperdal Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BB |
Cariprazine AbbVie | Phase 3 | BB |
Karxt Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | B |
Lumateperone Intra-Cellular Therapies, Inc. | Phase 3 | B |
View all 15 →
Same molecule, other indications
Epi-743 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →